An overview of the TAXUS® Express®, paclitaxel-eluting stent clinical trial program

John M. Lasala, Gregg W. Stone, Keith D. Dawkins, Patrick W. Serruys, Antonio Colombo, Eberhard Grube, Joerg Koglin, Stephen Ellis

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Restenosis remains a problem following percutaneous coronary intervention in patients with coronary artery disease. Drug-eluting stents (DES), which combine mechanical and pharmacologic properties, have been shown to prevent or reduce neointimal growth after deployment. This review describes the TAXUS paclitaxel-eluting stent clinical trial expansion program (TAXUS® Express®, Boston Scientific, Natick, MA). This program comprises the largest data set of randomized controlled trials (RCTs) of DES to date, with over 6,200 patients enrolled since 2000. The program includes treatment of de novo lesions, as well as higher-risk lesion and patient populations. In this review, we discuss the results from the TAXUS family of randomized clinical trials, and compare the findings with data from TAXUS registries. The data from the randomized clinical trials suggest that the paclitaxel-eluting stent provides consistent and durable benefits across multiple lesion and patient types. Evidence from peri-and postapproval registries, where patient populations are more heterogeneous than those eligible and included in the RCTs, corroborate these findings, with overall low rates of cardiac events, including reinterventions.

Original languageEnglish
Pages (from-to)422-431
Number of pages10
JournalJournal of Interventional Cardiology
Volume19
Issue number5
DOIs
Publication statusPublished - Oct 2006

Fingerprint

Paclitaxel
Stents
Clinical Trials
Randomized Controlled Trials
Drug-Eluting Stents
Registries
Percutaneous Coronary Intervention
Population
Coronary Artery Disease
Growth
Therapeutics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Lasala, J. M., Stone, G. W., Dawkins, K. D., Serruys, P. W., Colombo, A., Grube, E., ... Ellis, S. (2006). An overview of the TAXUS® Express®, paclitaxel-eluting stent clinical trial program. Journal of Interventional Cardiology, 19(5), 422-431. https://doi.org/10.1111/j.1540-8183.2006.00183.x

An overview of the TAXUS® Express®, paclitaxel-eluting stent clinical trial program. / Lasala, John M.; Stone, Gregg W.; Dawkins, Keith D.; Serruys, Patrick W.; Colombo, Antonio; Grube, Eberhard; Koglin, Joerg; Ellis, Stephen.

In: Journal of Interventional Cardiology, Vol. 19, No. 5, 10.2006, p. 422-431.

Research output: Contribution to journalArticle

Lasala, JM, Stone, GW, Dawkins, KD, Serruys, PW, Colombo, A, Grube, E, Koglin, J & Ellis, S 2006, 'An overview of the TAXUS® Express®, paclitaxel-eluting stent clinical trial program', Journal of Interventional Cardiology, vol. 19, no. 5, pp. 422-431. https://doi.org/10.1111/j.1540-8183.2006.00183.x
Lasala, John M. ; Stone, Gregg W. ; Dawkins, Keith D. ; Serruys, Patrick W. ; Colombo, Antonio ; Grube, Eberhard ; Koglin, Joerg ; Ellis, Stephen. / An overview of the TAXUS® Express®, paclitaxel-eluting stent clinical trial program. In: Journal of Interventional Cardiology. 2006 ; Vol. 19, No. 5. pp. 422-431.
@article{76d84757d13948c7870d0baa4af6da23,
title = "An overview of the TAXUS{\circledR} Express{\circledR}, paclitaxel-eluting stent clinical trial program",
abstract = "Restenosis remains a problem following percutaneous coronary intervention in patients with coronary artery disease. Drug-eluting stents (DES), which combine mechanical and pharmacologic properties, have been shown to prevent or reduce neointimal growth after deployment. This review describes the TAXUS paclitaxel-eluting stent clinical trial expansion program (TAXUS{\circledR} Express{\circledR}, Boston Scientific, Natick, MA). This program comprises the largest data set of randomized controlled trials (RCTs) of DES to date, with over 6,200 patients enrolled since 2000. The program includes treatment of de novo lesions, as well as higher-risk lesion and patient populations. In this review, we discuss the results from the TAXUS family of randomized clinical trials, and compare the findings with data from TAXUS registries. The data from the randomized clinical trials suggest that the paclitaxel-eluting stent provides consistent and durable benefits across multiple lesion and patient types. Evidence from peri-and postapproval registries, where patient populations are more heterogeneous than those eligible and included in the RCTs, corroborate these findings, with overall low rates of cardiac events, including reinterventions.",
author = "Lasala, {John M.} and Stone, {Gregg W.} and Dawkins, {Keith D.} and Serruys, {Patrick W.} and Antonio Colombo and Eberhard Grube and Joerg Koglin and Stephen Ellis",
year = "2006",
month = "10",
doi = "10.1111/j.1540-8183.2006.00183.x",
language = "English",
volume = "19",
pages = "422--431",
journal = "Journal of Interventional Cardiology",
issn = "0896-4327",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - An overview of the TAXUS® Express®, paclitaxel-eluting stent clinical trial program

AU - Lasala, John M.

AU - Stone, Gregg W.

AU - Dawkins, Keith D.

AU - Serruys, Patrick W.

AU - Colombo, Antonio

AU - Grube, Eberhard

AU - Koglin, Joerg

AU - Ellis, Stephen

PY - 2006/10

Y1 - 2006/10

N2 - Restenosis remains a problem following percutaneous coronary intervention in patients with coronary artery disease. Drug-eluting stents (DES), which combine mechanical and pharmacologic properties, have been shown to prevent or reduce neointimal growth after deployment. This review describes the TAXUS paclitaxel-eluting stent clinical trial expansion program (TAXUS® Express®, Boston Scientific, Natick, MA). This program comprises the largest data set of randomized controlled trials (RCTs) of DES to date, with over 6,200 patients enrolled since 2000. The program includes treatment of de novo lesions, as well as higher-risk lesion and patient populations. In this review, we discuss the results from the TAXUS family of randomized clinical trials, and compare the findings with data from TAXUS registries. The data from the randomized clinical trials suggest that the paclitaxel-eluting stent provides consistent and durable benefits across multiple lesion and patient types. Evidence from peri-and postapproval registries, where patient populations are more heterogeneous than those eligible and included in the RCTs, corroborate these findings, with overall low rates of cardiac events, including reinterventions.

AB - Restenosis remains a problem following percutaneous coronary intervention in patients with coronary artery disease. Drug-eluting stents (DES), which combine mechanical and pharmacologic properties, have been shown to prevent or reduce neointimal growth after deployment. This review describes the TAXUS paclitaxel-eluting stent clinical trial expansion program (TAXUS® Express®, Boston Scientific, Natick, MA). This program comprises the largest data set of randomized controlled trials (RCTs) of DES to date, with over 6,200 patients enrolled since 2000. The program includes treatment of de novo lesions, as well as higher-risk lesion and patient populations. In this review, we discuss the results from the TAXUS family of randomized clinical trials, and compare the findings with data from TAXUS registries. The data from the randomized clinical trials suggest that the paclitaxel-eluting stent provides consistent and durable benefits across multiple lesion and patient types. Evidence from peri-and postapproval registries, where patient populations are more heterogeneous than those eligible and included in the RCTs, corroborate these findings, with overall low rates of cardiac events, including reinterventions.

UR - http://www.scopus.com/inward/record.url?scp=33749433722&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749433722&partnerID=8YFLogxK

U2 - 10.1111/j.1540-8183.2006.00183.x

DO - 10.1111/j.1540-8183.2006.00183.x

M3 - Article

C2 - 17020567

AN - SCOPUS:33749433722

VL - 19

SP - 422

EP - 431

JO - Journal of Interventional Cardiology

JF - Journal of Interventional Cardiology

SN - 0896-4327

IS - 5

ER -